{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-159134","form_type":"8-K","ticker":null,"cik":"0001501756","company_name":"Adverum Biotechnologies, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.702939+00:00","generated_at":"2026-06-01T05:02:08.456561+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Adverum appoints Rabia Ozden as CMO, Szilard Kiss to board, effective June 10","bullets":["Rabia Gurses Ozden, M.D. appointed Chief Medical Officer effective June 10, 2024.","Ozden resigned from the Board and R&D Committee effective same date.","Szilard Kiss, M.D. appointed as Class III director; expected to join R&D Committee.","Kiss is a retina specialist, professor at Weill Cornell, and CMO of Blue Gen Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-159134","json":"https://secwatch.observer/filing/0001193125-24-159134.json","markdown":"https://secwatch.observer/filing/0001193125-24-159134.md","text":"https://secwatch.observer/filing/0001193125-24-159134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/d849862d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:02:08.456561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e80a83d2b","claim":"Rabia Gurses Ozden, M.D. was appointed as Chief Medical Officer at Adverum Biotechnologies, Inc..","evidence_excerpt":"appointed Rabia Gurses Ozden, M.D. as the Company’s Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"a6018906ac","claim":"Rabia Gurses Ozden, M.D. resigned as Director at Adverum Biotechnologies, Inc..","evidence_excerpt":"Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c67325c879","claim":"Szilárd Kiss, M.D. was appointed as Director at Adverum Biotechnologies, Inc..","evidence_excerpt":"appointed Szilárd Kiss, M.D. as a director to fill the vacancy on the Board created by Dr. Ozden’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}